# GHK-Cu Dosage in Preclinical Studies: Concentrations, Routes, and Durations > GHK-Cu dosage in preclinical research: nanomolar concentrations in fibroblast cultures, 0.1–1% topical in 12-week human studies, liposomal formulations in animal wound models. Research-context only — no human protocols. ## GHK-Cu Dosage in Preclinical Studies GHK-Cu has been studied across a concentration range spanning twelve orders of magnitude — from 10⁻¹² M (picomolar, the lowest concentration showing measurable collagen stimulation in fibroblast cultures)[1] to 10⁻⁶ M (micromolar, the upper bound of most in vitro gene-expression studies).[2] The dose-response pattern documented in fibroblast collagen assays is: threshold activity at 10⁻¹² M; maximal stimulation at 10⁻⁹ M (1 nanomolar); the response plateau beginning at 10⁻⁸ M.[1] Published research concentrations organized by model type: - In vitro fibroblast culture (collagen/elastin/ECM assays): 1–10 nM (10⁻⁹ to 10⁻⁸ M). Maquart et al. 1988 [1]; Pickart et al. 2015 [4]. - Gene expression arrays: Nanomolar to micromolar range (10⁻¹² to 10⁻⁶ M). Pickart and Margolina 2018 [2]; Pickart et al. 2017 [7]. - Topical human skin studies: 0.1–1% GHK-Cu in facial cream, applied once daily for 12 weeks. Pickart et al. 2015 [13]; Mortazavi et al. 2024 [14]. - Mouse burn/scald model: Liposomal GHK-Cu formulation. Wang et al. 2017 [5]. - Mouse LPS lung injury: Dose not specified in abstract. Park et al. 2016 [6]. - Intranasal aging mouse model: 15 mg/kg intranasal, 8-week study. - Anti-fibrotic myofibroblast (anti-aging): Dose-dependent range in migration assay. He et al. 2024 [17]. - GHK-AgNP wound composite: Composite formulation. Adnan et al. 2025 [20]. ## GHK-Cu Dosage Protocol in Research Topical Studies Published topical studies applied GHK-Cu formulations at 0.1–1% concentration once or twice daily to clean skin, typically after cleansing and before heavier moisturizers, for study durations of 8–12 weeks.[13, 14] The largest human study (71 women, Pickart et al. 2015) used daily application for 12 weeks.[13] Skin penetration note: native GHK-Cu penetrates intact human stratum corneum poorly due to its hydrophilic character and ionic copper center.[19] Liposomal encapsulation has been studied to improve delivery, but as of 2025 there are no standardized analytical methods to quantify how much encapsulated GHK-Cu actually reaches viable skin layers; the methodological gap is identified in a 2025 Molecules review.[19] ## Pharmacokinetics: GHK-Cu Half-Life Formal plasma pharmacokinetic data for GHK-Cu in humans is not available in published peer-reviewed literature. No published study has characterized half-life, volume of distribution, or plasma clearance in human subjects following topical, subcutaneous, or intravenous administration. ### What Is the GHK-Cu Half-Life? Plasma half-life data for GHK-Cu in humans is not available in published literature.[19] In topical studies, retention in skin layers has not been formally characterized via pharmacokinetic methods. No clinical pharmacokinetic study measuring absorption, half-life, or clearance for any route of administration has been completed and published. ## Daily vs. Cyclical Dosing in Research Models Preclinical studies have used both daily and cyclical dosing schedules depending on the application and model. The published topical human studies used daily application over 12-week windows.[13] No human consensus dosing protocol exists. Human clinical data is limited to topical cosmetic studies of 8–12 weeks; no dose-finding study for any other route has been published. ## Duration of Use in Published Studies The longest published topical human studies ran 12 weeks.[13, 14] No long-term (>6 month) safety or efficacy data exists in peer-reviewed human trials for any route of administration. The 2024 BioImpacts systematic review identifies this duration gap as a critical limitation of the GHK-Cu human evidence base.[14] ## Formulation Stability and Storage GHK-Cu is sensitive to strong acids. Low-pH formulations — vitamin C serums at pH <3.5, AHA/BHA peels — can dissociate the copper-peptide complex, reducing the biologically active chelated form.[19] In topical formulations, simultaneous application with strong acids is identified as a stability risk in both the research literature and formulation reviews. ## References [1] Maquart FX, et al. FEBS Letters. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/ [2] Pickart L, Margolina A. IJMS. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ [4] Pickart L, et al. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ [5] Wang X, et al. Wound Repair and Regeneration. 2017;25(2):270-278. https://pubmed.ncbi.nlm.nih.gov/28370978/ [6] Park J, et al. Oncotarget. 2016;7(36):58405-58417. https://pmc.ncbi.nlm.nih.gov/articles/PMC5295439/ [7] Pickart L, et al. Brain Sciences. 2017;7(2):20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5332963/ [13] Pickart L, et al. BioMed Research International. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ [14] Mortazavi SM, et al. BioImpacts. 2024. https://pubmed.ncbi.nlm.nih.gov/39963574/ [15] Miller TR, et al. Archives of Facial Plastic Surgery. 2006;8(4):252-259. https://pubmed.ncbi.nlm.nih.gov/16847171/ [17] He Q, Mazzola J, Ladiges W. Aging Pathobiology and Therapeutics. 2024;6(4):186-190. https://pmc.ncbi.nlm.nih.gov/articles/PMC12352503/ [19] Ogorek K, et al. Molecules. 2025;30(1):136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/ [20] Adnan SB, et al. International Journal of Medical Sciences. 2025;22(16):4175-4200. --- Compiled from the gene-modulation script of the published GHK-Cu record — copper-biology indexed, not prescribed.